Technical Analysis for PRME - Prime Medicine, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 7.08 | 0.57% | 0.04 |
PRME closed up 0.57 percent on Friday, May 17, 2024, on 83 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.57% | |
| Weak + Overbought | Other | 0.57% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| 1.5x Volume Pace | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
| Down 2 % | 2 days ago |
| Down 1% | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.195 |
| 52 Week Low | 4.11 |
| Average Volume | 736,524 |
| 200-Day Moving Average | 8.20 |
| 50-Day Moving Average | 6.09 |
| 20-Day Moving Average | 5.54 |
| 10-Day Moving Average | 6.16 |
| Average True Range | 0.53 |
| RSI (14) | 68.75 |
| ADX | 28.19 |
| +DI | 29.20 |
| -DI | 12.75 |
| Chandelier Exit (Long, 3 ATRs) | 5.60 |
| Chandelier Exit (Short, 3 ATRs) | 5.69 |
| Upper Bollinger Bands | 7.20 |
| Lower Bollinger Band | 3.88 |
| Percent B (%b) | 0.96 |
| BandWidth | 59.87 |
| MACD Line | 0.28 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.2711 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.55 | ||||
| Resistance 3 (R3) | 7.53 | 7.35 | 7.47 | ||
| Resistance 2 (R2) | 7.35 | 7.23 | 7.36 | 7.44 | |
| Resistance 1 (R1) | 7.22 | 7.16 | 7.29 | 7.24 | 7.42 |
| Pivot Point | 7.04 | 7.04 | 7.08 | 7.05 | 7.04 |
| Support 1 (S1) | 6.91 | 6.92 | 6.98 | 6.93 | 6.74 |
| Support 2 (S2) | 6.73 | 6.85 | 6.74 | 6.72 | |
| Support 3 (S3) | 6.60 | 6.73 | 6.69 | ||
| Support 4 (S4) | 6.62 |
